NASDAQ IVCP Swiftmerge Acquisition Corp (“Swiftmerge”), a $225 million innovative healthcare investment corporation and a special purpose acquisition company, has announced the signing of a non-binding letter of intent (“LOI”) for a business combination with HDL Therapeutics Inc. (“HDL Therapeutics”), a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy for reducing coronary atheroma in homozygous familial hypercholesterolemia (HoFH) patients. HDL Therapeutics’ platform, removes the highest risk plaques in coronary arteries that tend to rupture causing heart attacks and stroke.
Read the full article: HDL Therapeutics Inc Plans to Become Publicly Traded via a Business Combination with $225M Swiftmerge (NASDAQ: IVCP) with Goal to Transform Cardiovascular Disease Treatment //
Source: https://www.businesswire.com/news/home/20230424005819/en/HDL-Therapeutics-Inc-Plans-to-Become-Publicly-Traded-via-a-Business-Combination-With-225-Million-Swiftmerge-NASDAQ-IVCP-With-Goal-to-Transform-Cardiovascular-Disease-Treatment